|
1
|
Talbot R and Kirkham S: Colorectal cancer.
Lancet. 376:3302010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fujita T: Colorectal cancer. Lancet.
376:331–332. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Brenner H, Kloor M and Pox CP: Colorectal
cancer. Lancet. 383:1490–1502. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Visone R and Croce CM: MiRNAs and cancer.
Am J Pathol. 174:1131–1138. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lujambio A and Lowe SW: The microcosmos of
cancer. Nature. 482:347–355. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Croce CM: miRNAs in the spotlight:
Understanding cancer gene dependency. Nat Med. 17:935–936. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bao Y, Chen Z, Guo Y, Feng Y, Li Z, Han W,
Wang J, Zhao W, Jiao Y, Li K, et al: Tumor suppressor microRNA-27a
in colorectal carcinogenesis and progression by targeting SGPP1 and
Smad2. PLoS One. 9:e1059912014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang Z, Sun X, Wang Y, Liu X, Xuan Y and
Hu S: Association between miR-27a genetic variants and
susceptibility to colorectal cancer. Diagn Pathol. 9:1462014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yuan W, Sui C, Liu Q, Tang W, An H and Ma
J: Up-regulation of microRNA-145 associates with lymph node
metastasis in colorectal cancer. PLoS One. 9:e1020172014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Feng Y, Zhu J, Ou C, Deng Z, Chen M, Huang
W and Li L: MicroRNA-145 inhibits tumour growth and metastasis in
colorectal cancer by targeting fascin-1. Br J Cancer.
110:2300–2309. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ding Q, Chang CJ, Xie X, Xia W, Yang JY,
Wang SC, Wang Y, Xia J, Chen L, Cai C, et al: APOBEC3G promotes
liver metastasis in an orthotopic mouse model of colorectal cancer
and predicts human hepatic metastasis. J Clin Invest.
121:4526–4536. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yau TO, Wu CW, Dong Y, Tang CM, Ng SS,
Chan FK, Sung JJ and Yu J: microRNA-221 and microRNA-18a
identification in stool as potential biomarkers for the
non-invasive diagnosis of colorectal carcinoma. Br J Cancer.
111:1765–1771. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ress AL, Stiegelbauer V, Winter E,
Schwarzenbacher D, Kiesslich T, Lax S, Jahn S, Deutsch A,
Bauernhofer T, Ling H, et al: MiR-96-5p influences cellular growth
and is associated with poor survival in colorectal cancer patients.
Mol Carcinog. 54:1442–1450. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang Y, Tang Q, Li M, Jiang S and Wang X:
MicroRNA-375 inhibits colorectal cancer growth by targeting PIK3CA.
Biochem Biophys Res Commun. 444:199–204. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Geng L, Sun B, Gao B, Wang Z, Quan C, Wei
F and Fang XD: MicroRNA-103 promotes colorectal cancer by targeting
tumor suppressor DICER and PTEN. Int J Mol Sci. 15:8458–8472. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen HY, Lin YM, Chung HC, Lang YD, Lin
CJ, Huang J, Wang WC, Lin FM, Chen Z, Huang HD, et al: miR-103/107
promote metastasis of colorectal cancer by targeting the metastasis
suppressors DAPK and KLF4. Cancer Res. 72:3631–3641. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hong Z, Feng Z, Sai Z and Tao S: PER3, a
novel target of miR-103, plays a suppressive role in colorectal
cancer in vitro. BMB Rep. 47:500–505. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhao B, Lei QY and Guan KL: The Hippo-YAP
pathway: New connections between regulation of organ size and
cancer. Curr Opin Cell Biol. 20:638–646. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Trajkovski M, Hausser J, Soutschek J, Bhat
B, Akin A and Zavolan M: MicroRNAs 103 and 107 regulate insulin
sensitivity. Nature. 474:649–653. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ellis KL, Cameron VA, Troughton RW,
Frampton CM, Ellmers LJ and Richards AM: Circulating microRNAs as
candidate markers to distinguish heart failure in breathless
patients. Eur J Heart Fail. 15:1138–1147. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yu D, Zhou H, Xun Q, Xu X, Ling J and Hu
Y: microRNA-103 regulates the growth and invasion of endometrial
cancer cells through the downregulation of tissue inhibitor of
metalloproteinase 3. Oncol Lett. 3:1221–1226. 2012.PubMed/NCBI
|
|
24
|
Pan D: The hippo signaling pathway in
development and cancer. Dev Cell. 19:491–505. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Takahashi Y, Miyoshi Y, Morimoto K,
Taguchi T, Tamaki Y and Noguchi S: Low LATS2 mRNA level can predict
favorable response to epirubicin plus cyclophosphamide, but not to
docetaxel, in breast cancers. J Cancer Res Clin Oncol. 133:501–509.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Strazisar M, Mlakar V and Glavac D: LATS2
tumour specific mutations and down-regulation of the gene in
non-small cell carcinoma. Lung Cancer. 64:257–262. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yang X, Yu J, Yin J, Xiang Q, Tang H and
Lei X: MiR-195 regulates cell apoptosis of human hepatocellular
carcinoma cells by targeting LATS2. Pharmazie. 67:645–651.
2012.PubMed/NCBI
|
|
28
|
Li J, Chen X, Ding X, Cheng Y, Zhao B, Al
Hezaimik, Hakem R, Guan KL, Wang CY and Lai ZC: LATS2 suppresses
oncogenic Wnt signaling by disrupting beta-catenin/BCL9
interaction. Cell Rep. 5:1650–1663. 2013. View Article : Google Scholar : PubMed/NCBI
|
